Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 7Phase 1/2 5Phase 3 4Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Advanced Gastric or EGJ Cancer 1

Interventions

Oxaliplatin 11Docetaxel 8Fluorouracil 6Capecitabine 6Trastuzumab 5Leucovorin 5Drug Therapy 5apatinib 4S 1 (combination) 4Tegafur 3Paclitaxel 3Nivolumab 3Irinotecan 3Cisplatin 3sintilimab 2disitamab vedotin 2Surgical Procedures, Operative 2Standard of Care 2Ramucirumab 2Hyperthermic Intraperitoneal Chemotherapy 2Epirubicin 2vinflunine 1toripalimab 1titanium silicide 1tislelizumab 1taxane 1polysaccharide-K 1pertuzumab 1margetuximab 1gimeracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Stomach Neoplasms × Ramucirumab × Clear all
NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

ALX Oncology Inc.

Phase 2/3 Active not recruiting
127 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02661971 2022-07-11

RAMSES/FLOT7

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2/3 Completed
180 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡